Groundbreaking hip-focused physical therapy reduces low back pain
When the University of Delaware’s Gregory Hicks started his research career two decades ago, he was one of only a few people in the United States studying chronic… read more.
When the University of Delaware’s Gregory Hicks started his research career two decades ago, he was one of only a few people in the United States studying chronic… read more.
Dulaglutide. a Type 2 diabetes treatment, appears to significantly lower the risk of weight gain among women who have stopped smoking, researchers reported after a secondary analysis of… read more.
The FDA has approved eflornithine (Iwilfin, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least… read more.
Since the COVID-19 pandemic began, extensive research has emerged detailing the virus’s ability to attack multiple organ systems, potentially resulting in a set of enduring and often disabling… read more.
Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year’s discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of… read more.
On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
Ultrafast laser technology continues to surprise. While research in this field may seem rather abstract at first glance, it very often leads to concrete applications. This is particularly… read more.
People who live in neighborhoods with higher levels of poverty and unemployment are less likely to fill their heart-failure drug prescriptions than those living in wealthier areas, a… read more.
UK organisations responsible for protecting the public from prescription-only drug adverts are putting patients at risk from the harms of weight loss drugs by not enforcing the law,… read more.
Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.
The vast majority of older adults – 83% — think health insurers should cover medications that can help people with obesity manage their weight, a new poll of… read more.
Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.